ADDvise Group has had a positive turnover growth in 2014. However, a
slightly weaker than-expected sales in the fourth quarter has resulted
in that the previously announced turnover and EBITDA forecast of 149
MSEK and 11 MSEK will not be met. Net sales for the full year 2014 is
estimated to approximately 138 MSEK with an EBITDA before acquisition
costs of approximately 6.8 MSEK in accordance with IFRS. The
corresponding numbers for 2013 amounted to 120 MSEK in net sales and
EBITDA before acquisition costs of 6.1 MSEK.
\- A shift of orders from the fourth quarter 2014 to the first quarter
2015 is the main reason why the full year forecast will not be met. In
return, we have had a historically strong start of 2015, says Rikard
Akhtarzand CEO of ADDvise in a comment on today\'s adjusted forecast.
ADDvise Year-end Report for 2014 will be published on February 19th
2015.
Rikard Akhtarzand, VD +46 765-25 90 71
rikard.akhtarzand@addvisegroup.se
About ADDvise Lab Solutions AB
ADDvise Lab Solutions AB (publ) is an expansive group which through its
subsidiaries IM-Medico Svenska AB, KEBO Inredningar Sverige AB, ADDvise
Tillquist AB, Sonesta Medical AB, Sonesta Medical Inc and Surgical
Tables Inc. offers comprehensive solutions in the form of products and
services to healthcare and research facilities. ADDvise Group\'s
customers are located in both the private and public sectors. The
Company\'s share is listed on First North and Mangold Fondkommission AB,
+46 8-503015 50, is the company\'s Certified Adviser and liquidity
provider.
